The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells

Cancers, Free Full-Text

Trastuzumab MedChemExpress (MCE) Life Science Reagents

PDF) A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response

Cancers, Free Full-Text

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells

HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin

NCT-58 (CAS Number: 2411429-33-7)

Emerging insights into mechanisms of trastuzumab resistance in HER2-positive cancers - ScienceDirect

Cancers, Free Full-Text

Detailed curriculum vitae of HER2-targeted therapy - ScienceDirect

Role of Notch signaling on HER2 expression of tumor-initiating cells.